Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.53 |
| ▸ | MTOR | P42345 | 11/20 | 0.51 |
| ▸ | ATM | Q13315 | 15/20 | 0.50 |
| ▸ | ATR | Q13535 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367961 | 0.86 | PIK3CA (0.48) | PIK3CAMTORATMATR | |
| SCHEMBL367962 | 0.86 | PIK3CA (0.48) | PIK3CAMTORATMATR | |
| SCHEMBL9905072 | 0.83 | PIK3CD (0.60) | PIK3CAMTORATMATR | |
| SCHEMBL9905352 | 0.79 | ATM (0.67) | PIK3CAMTORATMATR | |
| SCHEMBL9905279 | 0.78 | PIK3CA (0.51) | PIK3CAMTORATMATR | |
| SCHEMBL16055759 | 0.78 | MTOR (0.53) | PIK3CAMTORATMATR | |
| SCHEMBL3513926 | 0.77 | PIK3CA (0.47) | PIK3CAMTORATMATR | |
| SCHEMBL16054954 | 0.77 | MTOR (0.49) | PIK3CAMTORATMATR | |
| SCHEMBL9905281 | 0.77 | PIK3CA (0.52) | PIK3CAMTORATMATR | |
| SCHEMBL3513940 | 0.77 | PIK3CA (0.46) | PIK3CAMTORATMATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | PIRAMAL ENTERPRISES LIMITED` (IN) | 2013-11-21 | — | — | US | claimed |
| EP-2648733-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | Piramal Enterprises Limited (IN) | 2013-10-16 | — | — | EP | claimed |
| WO-2012077031-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-06-14 | — | — | WO | claimed |
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | PIRAMAL ENTERPRISES LIMITED` (IN) | 2013-11-21 | — | — | US | disclosed |
| EP-2648733-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | Piramal Enterprises Limited (IN) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012077031-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | FLT4, CDK4, CDK2 | PIK3CA 154/4885MTOR 220/4885ATM 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.